Novartis: India rejects patent plea for cancer drug Glivec

Help

India's Supreme Court has rejected a plea by Novartis to patent an updated version of its cancer drug, Glivec.

The Swiss drugmaker had been denied a patent by Indian authorities on the grounds that the new version was only slightly different from the old.

There were concerns that a patent could threaten access to cheap generic versions of drugs in poorer countries.

But some Western companies had warned that a decision against Novartis could discourage investment in research.

Shilpa Kannan reports from Delhi.

BBC © 2014 The BBC is not responsible for the content of external sites. Read more.

This page is best viewed in an up-to-date web browser with style sheets (CSS) enabled. While you will be able to view the content of this page in your current browser, you will not be able to get the full visual experience. Please consider upgrading your browser software or enabling style sheets (CSS) if you are able to do so.